UBS Group AG Sells 23,479 Shares of AxoGen, Inc. $AXGN

UBS Group AG lowered its stake in AxoGen, Inc. (NASDAQ:AXGN) by 20.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 90,778 shares of the medical equipment provider’s stock after selling 23,479 shares during the quarter. UBS Group AG owned 0.20% of AxoGen worth $2,971,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Aquatic Capital Management LLC lifted its position in AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 1,269 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in AxoGen in the fourth quarter valued at approximately $98,000. FNY Investment Advisers LLC purchased a new position in shares of AxoGen during the third quarter valued at approximately $64,000. Tower Research Capital LLC TRC increased its stake in shares of AxoGen by 189.9% during the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 3,327 shares during the period. Finally, State of Wyoming purchased a new position in shares of AxoGen during the second quarter valued at approximately $69,000. Institutional investors own 80.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Citigroup reissued an “outperform” rating on shares of AxoGen in a research note on Wednesday, April 29th. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday. HC Wainwright boosted their target price on AxoGen from $39.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Raymond James Financial reissued an “outperform” rating and set a $48.00 target price on shares of AxoGen in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company boosted their target price on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

Insider Transactions at AxoGen

In related news, Director John Johnson sold 11,050 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the sale, the director directly owned 11,050 shares of the company’s stock, valued at $478,023. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amy Mcbride Wendell sold 1,647 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the completion of the sale, the director directly owned 93,826 shares in the company, valued at approximately $3,996,987.60. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 34,262 shares of company stock valued at $1,440,250 in the last three months. Company insiders own 2.44% of the company’s stock.

AxoGen Price Performance

AXGN opened at $40.90 on Tuesday. The stock has a market capitalization of $2.18 billion, a PE ratio of -63.91 and a beta of 1.17. The stock’s 50 day moving average price is $36.80 and its 200-day moving average price is $32.97. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $45.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to analysts’ expectations of $57.85 million. AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%. On average, equities research analysts predict that AxoGen, Inc. will post -0.3 EPS for the current year.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.